Attention Deficit Hyperactivity Disorder Study: Methylphenidate v. Atomoxetine

ID Number 03-0612-02001

Principal Investigator(s)
Jeffrey Newcorn

Department(s) or Division(s)


The purpose of this federally-funded research study is to examine and compare mechanisms of action of two FDA approved medications for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). If volunteers are participating in the medication treatment study that examines response to Methylphenidate and Atomoxetine [GCO 03-0612 (0001)], are between the ages 7 and 17 years, and have no metal permanently placed in their bodies, they may be eligible to participate in this scanning study.This study uses fMRI technology to take pictures of participants' brains while they lie in a scanner and play videogames. 

Contact Information
Beth K. Krone, CRC
(212) 659-8833

Recruiting Patients: No